Clinical Trial Update: An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3). [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating organ-preserving strategies after chemoradiotherapy with immunotherapy for esophageal cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Snippet

Sponsor: Ruijin Hospital | Conditions: Esophageal Cancer | Phase 3 | Status: RECRUITING